Integrin αvβ3 Upregulation in Response to Nutrient Stress Promotes Lung Cancer Cell Metabolic Plasticity

Arin Nam1, Shashi Jain1,2, Chengsheng Wu1, Alejandro Campos1, Ryan M. Shepard1, Ziqi Yu1, Joshua P. Reddy1, Tami Von Schalscha1, Sara M. Weis1, Mark Onaitis5, Hiromi I. Wettersten1, and David A. Cheresh1

Abstract

Cancer stem/tumor-initiating cells display stress tolerance and metabolic flexibility to survive in a harsh environment with limited nutrient and oxygen availability. The molecular mechanisms underlying this phenomenon could provide targets to prevent metabolic adaptation and halt cancer progression. Here, we showed in cultured cells and live human surgical biopsies of non–small cell lung cancer that nutrient stress drives the expression of the epithelial cancer stem cell marker integrin αvβ3 via upregulation of the β3 subunit, resulting in a metabolic reprogramming cascade that allows tumor cells to thrive despite a nutrient-limited environment. Although nutrient deprivation is known to promote acute, yet transient, activation of the stress sensor AMP-activated protein kinase (AMPK), stress-induced αvβ3 expression via Src activation unexpectedly led to secondary and sustained AMPK activation. This resulted in the nuclear localization of peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC1α) and upregulation of glutamine metabolism, the tricarboxylic acid cycle, and oxidative phosphorylation. Pharmacological or genetic targeting of this axis prevented lung cancer cells from evading the effects of nutrient stress, thereby blocking tumor initiation in mice following orthotopic implantation of lung cancer cells. These findings reveal a molecular pathway driven by nutrient stress that results in cancer stem cell reprogramming to promote metabolic flexibility and tumor initiation.

Significance: Upregulation of integrin αvβ3, a cancer stem cell marker, in response to nutrient stress activates sustained AMPK/PGC1α signaling that induces metabolic reprogramming in lung cancer cells to support their survival.

See related article by xxxx, p. xx

Introduction

Within the tumor microenvironment, cancer cells are often exposed to cellular stresses resulting from nutrient deprivation, hypoxia, reactive oxygen species, and exposure to therapeutics. Cancer cells that can adapt to such stresses gain an aggressive phenotype and display the properties of cancer stem/tumor-initiating cells (1–3). Accordingly, cancer cells must adapt to variations in nutrient and oxygen availability (4, 5). Thus, metabolic flexibility represents a key benefit that cancer stem/tumor-initiating cells can invoke not only during tumor initiation at the primary site but also as they establish new colonies at metastatic sites. Therefore, targeting this metabolic adaptation might help control cancer progression (6). However, the molecular mechanism(s) through which cancer stem/tumor-initiating cells adapt to nutrient stress has not been fully defined.

Integrins are a family of adhesion receptors that enable cells to sense and respond to their microenvironment (7, 8). As the tumor is an evolving tissue that undergoes periods of regional nutrient deprivation, tumor cells must be able to sense and appropriately respond to this form of cellular stress to survive and contribute to tumor formation and progression. Previous studies have shown that integrin αvβ3 is both necessary and sufficient to induce tumor initiation, establishing it as both a marker and a driver of tumor stemness (3, 9). Here, we show that cultured non–small cell lung cancer (NSCLC) cells and fresh surgical biopsies from patients respond to nutrient stress by upregulating integrin β3 expression, leading to increased αvβ3 cell surface expression. This, in turn, triggers the anchorage-independent activation of a Src-signaling module that not only induces sustained activation of AMP-activated protein kinase (AMPK) but also converts the primary metabolic dependency from glycolysis to oxidative phosphorylation (OXPHOS), enabling cells to adapt to nutrient stress and gain tumor-initiating properties in vivo. Evidence suggests that targeting this signaling module not only reverses the metabolic adaptation brought on by integrin β3, but also blocks tumor initiation. These studies help explain how tumor cells can acquire a stem-like phenotype in response to stress via the upregulation of an integrin subunit.

Materials and Methods

Material details

Reagents

The following reagents were purchased from Selleckchem: OXPHOS complex I inhibitor, IACS-010759 (S8731); AMPK inhibitor, dorsomorphin (S7306); AMPK inhibitor, AICAR (S1802); PGC1α (proliferator-activated receptor-gamma coactivator 1α) inhibitor, SR-18292 (S8528); PGC1α inhibitor, ZLN005 (S7447); and Src inhibitor, saracatinib (S1006).
Cells

NSCLC cell lines HCC827 (grown in RPMI), H1650 (grown in RPMI), LLC (grown in DMEM), H1975 (grown in RPMI), and H1792 (grown in RPMI) were obtained from ATCC. Upon receipt, each cell line was expanded, cryopreserved as low-passage stocks, and tested for Mycoplasma using a MycoScope PCR Mycoplasma Detection Kit (Genlantis, MY01050). All the cell lines were used for 30 passages. For ectopic expression and genetic knockdown, cells were transfected with a vector control, full-length integrin β3, integrin β3/β1 chimera, mutant β3 (β3–759X), and/or luciferase using a lentiviral system, as previously described (3, 9). shRNAs were obtained from Horizon: nontargeting (shCTRL, RHS4743) and β3 knockdown (sh-β3.1: RHS4696–200690101, sh-β3.2:20069575, and sh-β3.3:201895199). For genetic knockout, Gibson assembly was performed to make gRNA, and β3 gRNA and Cas9 (Addgene, 44719) were transfected using Lipofectamine 3000 (Thermo Fisher Scientific, L3000001). The gRNA sequences are listed in Supplementary Table S1. ON-TARGETplus SMARTpool siRNAs were obtained from Horizon: Nontargeting (D-001810–10–05), STK11 (L-005035–00–0005), CAMKK2 (L-004842–00–0005), PRKAA1 (L-005027–00–0005), and PRKAA2 (L-005361–00–0005). Cells were transfected with siRNA using jetPRIME (Polyplus, 101000015) according to the manufacturer’s protocol.

All the cell-based assays were performed in suspension unless stated.

Method details

Quantitative RT-PCR

RNA was isolated using an RNeasy RNA Purification Kit (Qiagen, 75144) following the manufacturer’s instructions. cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 4368814), and RT-PCR was performed using CFX96 (Bio-Rad) with SYBR Green (Bio-Rad, 1725272). The primer sequences are listed in Supplementary Table S2.

Immunoblotting

Immunoblotting was performed as previously described (3). Briefly, cells were washed twice with 1X Hanks’ Balanced Salt Solution (HBSS) before lysing with 1X RIPA buffer containing protease and phosphatase inhibitors. Nuclear and cytoplasmic fractionation was performed using a Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, 788333) according to the manufacturer’s protocol. A BCA assay (Thermo Fisher Scientific, 23227) was performed, and the lysates were normalized. Sample buffer (NuPAGE LDS Sample Buffer 4X, Sigma, catalog #NP0007) and reducing agent (NuPAGE Sample Reducing Agent, Sigma, NP0009) were added to the lysate and then heated at 95°C for 5 minutes. Proteins (20 μg) were loaded onto an SDS-PAGE gel. Blocking was performed in 5% BSA in TBS, and probing was performed in 5% BSA in TBST buffer. LI-COR fluorescent secondary antibodies were used to visualize the protein bands using the Odyssey CLX machine and software (LI-COR). The antibodies used in this study are listed in Supplementary Table S3.

Flow cytometry

Cell pellets were washed with PBS, blocked with 1% BSA in PBS for 30 minutes at room temperature, and stained with or without indicated primary antibodies with fluorescently labeled secondary antibodies. Cells were incubated with propidium iodide (Sigma, P4864). Flow cytometry was performed on a BD Fortessa X-20 (BD Biosciences) analyzer, and the data were analyzed using FlowJo (Treestar) software.

Tissue-slice culture

Written informed consents from patients were received. The study was conducted in accordance with U.S. Common Rule. The study was approved by an institutional review board of University of California, San Diego.

Lung cancer tissues obtained at surgical resection were cut using a vibratome, as previously described (10). Briefly, the cancer tissues were embedded in 5% agar and sequentially sliced using a vibratome (200-μm-thick). The tissue slices were cultured in 0.4-μm PET Transwell with 10% FBS RPMI for 24 hours before being exposed to nutrient stress. After the exposure to the indicated stress for 96 hours, the slices were fixed in 10% formalin for IHC or stained with MitoTracker (Cell Signaling Technology, 9082), as described below.

IHC

Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded slides using an ImmPRESS Excel Staining Kit (Vector, MP-7602) following the manufacturer’s instructions. For both integrin β3 and ATP synthase B1, low-pH antigen retrieval was performed for 20 minutes at 95°C. The slides were imaged using an Olympus VS200 Slide Scanner (Olympus). For scoring integrin β3 and ATP synthase B1 staining, scanned images were scored for each protein expression by a blinded observer (score 0–4). To measure the ATP synthase B1-positive area, the area fraction of ATP synthase B1 with respect to the tumor tissue was calculated using ImageJ (NIH). Lung cancer microarray slides were purchased from Biomax (LC10011a and LC641).

MitoTracker staining

For tissue slice staining, after the indicated exposure to nutrient stress for 96 hours, tissue slices were stained with MitoTracker Red CMXRos (Cell Signaling Technology, 9082), as previously described (11). Briefly, tissue slices were incubated with Hoechst (5 μg/mL) and MitoTracker (200 nmol/L) in HBSS at 4°C for 20 minutes. The tissue slices were then mounted on glass slides using VECTASHIELD (Vector, H-1700).

Cells in suspension were stained and incubated with Accutase (Sigma, SCR005) for 3 minutes at 37°C. The cells were washed and stained with MitoTracker Red CMXRos (Cell Signaling Technology) for 20 minutes at 4°C. The cells were washed and blocked in 1% BSA in PBS for 30 minutes at room temperature, incubated with the anti-αvβ3 antibody for 1 hour at 4°C, and incubated with an anti-mouse IgG antibody and Hoechst (1 μg/mL) for 30 minutes at 4°C. The stained cells were plated on poly-L-lysine–coated 8-well chamber plates, and images were taken using a Nikon Eclipse C2 confocal microscope (Nikon).

MitoTracker signal intensity per cell was measured using ImageJ (NIH).

Viability assay

All cells used in this assay were transduced with luciferase lentivirus (Addgene, 17477). Cells with equivalent luciferase activity levels were used as the controls. At the end of the indicated incubation period, cells were subjected to 1:1 Steady-Glo (Promega, E2510) and incubated for 15 minutes before reading luminescence using Infinite 200 (TECAN).

Sphere formation assay

After exposure to the indicated stress for 96 hours, the cells were washed with HBSS and incubated with Accutase (Sigma, SCR005) for 3 minutes at 37°C to create a single-cell suspension. Then, 1 mL of methylcellulose stock media were added (R&D Systems, HSC001) to
Nutrient Stress-Induced Integrin αvβ3 Activates OXPHOS

A

B

C

D

E

F

G

AACRJournals.org

Cancer Res; 2024

OF3

Downloaded from http://aacrjournals.org/cancerres/article-pdf/doi/10.1158/0008-5472.CAN-23-2700/3441005/can-23-2700.pdf by Capital Medical University user on 17 April 2024

Brown, integrin β3; blue, hematoxylin; bar = 25 μm

Bar = 3 mm

AACRJournals.org

Cancer Res; 2024

OF3
Nam et al.

a 24-well nontreated plate. Then, 1 mL of the indicated media containing 4,000 cells were added. After 14 days, images of tumor colonies were captured and quantified using ImageJ (NIH).

RNA sequencing
RNA samples from LLC cells with and without ectopic integrin β3 expression incubated in suspension in 5% charcoal stripped FBS RPMI were submitted to Novogene for RNA sequencing (RNA-seq). RNA was extracted using the RNeasy RNA Purification Kit (Qiagen, 74104), following the manufacturer’s instructions. A total of 1 µg of RNA per sample was used to generate RNA-seq libraries using the NEBNext Ultra II RNA Library Prep Kit (NEB, E7770) following the manufacturer’s protocol. Libraries were sequenced using the Illumina NovaSeq platform, according to the manufacturer’s protocol. Paired-end reads were aligned to the mouse genome (GRCm38/mm10) using STAR 2.7.10b package. Aligned reads were subsequently counted using the subread feature counts package. Differentially expressed genes (DEGs) were identified using R package DESeq2 (+1.28.0). Benjamini and Hochberg corrections were used to calculate the adjusted P values ($P_{adj}$) for DEGs. Gene ontology analysis was performed using the Gene Set Enrichment Analysis (GSEA) platform.

Targeted metabolomics
Metabolites extracted from LLC cells with empty vector (+EV) and ectopic integrin β3 (+β3) incubated in suspension in 5% charcoal stripped FBS RPMI were subjected to targeted metabolomics at UCSD Biochemical Genetics and Metabolomics Laboratory (n = 5 per group). Negative and positive ionization panels and intracellular panels were run. Fold changes in metabolites in LLC+β3 versus LLC+EV were analyzed.

Glutamate measurements
Lung cancer cells were preincubated under the indicated conditions in suspension. The cells were collected and washed with PBS. Intra-cellular glutamate concentrations were measured using a Glutamine/Glutamate-Glo Assay kit (Promega, J7021) following the manufacturer’s instructions.

Oxygen consumption rate measurements
Oxygen consumption rate (OCR) was measured using an XF24 Seahorse Biosciences Extracellular Flux Analyzer (Seahorse Biosciences) as previously described (12). Briefly, after the indicated incubation in suspension, the cells were seeded in XF24-well plates (40,000 cells/well) for 2 hours before the assay. The XF-24 sensor cartridge was hydrated overnight at 37°C with 1 mL calibration buffer per well. The sensor cartridge was loaded with assay media (ports A, B, and C) to measure the basal OCR or with oligomycin (1 µmol/L, port A), carbonyl cyanide 4-(trifluromethoxy) phenylhydrazone (FCCP, 0.5 µmol/L, port B), and rotenone (1 µmol/L, port C) to measure the bioenergetic profile. OCR and extracellular acidification rate were measured under basal conditions.

Mouse study approval
All experiments involving mice were conducted under protocol S05018, approved by the University of California, San Diego Institutional Animal Care and Use Committee. All experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Lung orthotopic xenograft model
HCC827 cells with and without integrin β3 ectopic expression (5 × 10^6 cells in 50 µL of PBS) were injected into the lungs of athymic nude mice (8–10-week-old) from the Charles River Laboratories. Three months after the injection, the lungs with tumors were fixed in 10% formalin.

The indicated numbers of luciferase-expressing H1975 cells with and without integrin β3 knockout (in 50 µL of PBS) were injected into the lungs of athymic nude mice (8–10-week-old). The mice were injected with the vehicle or an OXPHOS inhibitor, IACS-10759 (5 mg/kg, 5 days on/2 days off, oral gavage, 100 µL/injection, 1.25 mg/mL in 0.5% methylcellulose in water). Tumor uptake and growth were monitored using the IVIS Spectrum (Revvity). The number of tumor-initiating cells per 10 million cells for each group was calculated using ELDA software (13).

Allograft model
LLC cells with and without integrin β3 ectopic expression (1 × 10^6 cells in 100 µL of PBS) were injected subcutaneously into the flanks of C57BL/6 mice (8–10-week-old) from Charles River Laboratories. Tumor uptake was monitored.

Statistical analysis
Student t-test, one-sample t-test, or ANOVA was performed to compare independent sample groups. Excel (Microsoft), Prism (GraphPad), and SPSS (IBM Analytics) were used for analysis.
Figure 2.
Integrin β3 mitigates nutrient stress by shifting cellular metabolic phenotype from glycolysis to glutamine metabolism/TCA cycle/OXPHOS. A, The table shows pathways with multiple metabolites that were significantly increased or decreased in integrin β3+ cells. PPP, pentose phosphate pathway; GMP, guanosine monophosphate; UMP, uridine monophosphate; CMP, cytidine monophosphate. Red, metabolites increased; blue, metabolites decreased in β3+ cells. B, The top 10 enriched pathways in LLC cells with ectopic integrin β3 versus empty vector are shown (sorted by FDR q values). C, Pathway map showing upregulated or downregulated metabolic pathways Red, increased; blue, decreased; squares, metabolites; circles, enzymes. Heat map of the OXPHOS genes in the comparison of LLC cells with ectopic integrin β3 (+β3) versus empty vector (+EV). D, Glutamate levels in LLC cells with and without ectopic integrin β3 (+β3 and +EV, respectively) or HCC827 exposed to low serum (0.5%) for 96 hours were measured. *P < 0.05.
Data availability

The RNA-seq data generated in this study are publicly available in Sequence Read Archive (SRA) at PRJNA1074809. All other raw data generated in this study are available upon request from the corresponding authors.

Results

NSCLC cells upregulate integrin αvβ3 to overcome nutrient stress

Integrin αvβ3 is a marker and driver of tumor initiation and drug resistance of NSCLC cells (3). Given that integrins sense microenvironmental changes, we investigated whether αvβ3 expression could be induced by nutrient stress. Subjecting cells in suspension to either low glucose or serum deprivation increased the mRNA expression of ITGB3 and, to a lesser extent, ITGB6 and ITGA5 integrin subunits previously linked to epithelial-to-mesenchymal transition (EMT, Fig. 1A; Supplementary Fig. S1A; refs. 7, 14). We further confirmed that exposing cells to nutrient stress induced a time-dependent increase in integrin β3 protein, as detected by immunoblotting (Fig. 1B; Supplementary Fig. S1B), and that cell surface expression of the integrin αvβ3 heterodimer following nutrient stress could be detected by flow cytometry at levels comparable with those observed in NSCLC cells with endogenous αvβ3 expression (Fig. 1C; Supplementary Fig. S1C). Because the αv subunit is widely expressed, presence of the αvβ3 heterodimer is dictated by expression of β3 subunit (15, 16). To assess whether nutrient stress upregulates integrin β3 expression in living human lung cancer tissues, we prepared thick sections from fresh lung cancer biopsies and exposed them to nutrient stress ex vivo (10). These living tissues were challenged with glucose deprivation and analyzed for integrin β3 expression by IHC. Consistent with our observations in established human NSCLC cells, integrin β3 expression was elevated in patient tissues deprived of glucose relative to tissues maintained at normal glucose levels (Fig. 1D), indicating that cells within a living human tumor respond to nutrient stress by upregulating αvβ3 expression.

To assess whether the nutrient stress-induced gain of integrin αvβ3 represents an adaptive response to mitigate nutrient stress, αvβ3-negative NSCLC cells were subjected to normal glucose versus low glucose (pre-stress) in suspension, and cell viability was measured after 24-hour challenge with decreasing concentrations of glucose or serum. Cells lacking endogenous β3 expression that were not pre-stressed showed a significant loss of viability with decreasing concentrations of glucose or serum (Fig. 1E; Supplementary Fig. S1D). In contrast, pre-stressed cells expressing scramble control shRNA showed only a moderate decrease in viability due to serum or glucose depletion, whereas cells expressing β3 shRNA, which prevented its upregulation during the pre-stress period, were as sensitive to nutrient stress as cells that were not subjected to pre-stress (Fig. 1E). These results demonstrate that cancer cells upregulate integrin αvβ3 as an adaptive response to overcome the effects of stress. Ectopic integrin β3 expression rescued the inherent "stress sensitivity" of αvβ3-negative cells, whereas β3 knockout compromised the inherent "stress tolerance" of αvβ3-positive cells, when evaluated using either cell viability (Fig. 1F; Supplementary Fig. S1E) or sphere formation assays (Fig. 1G).

These findings demonstrate that the ability of cancer cells to upregulate integrin β3 in response to nutrient stress allows them to convert to a stress tolerant state.

Integrin αvβ3 mitigates nutrient stress by shifting cellular metabolic phenotype from glycolysis to glutaminolysis/tricarboxylic acid (TCA) cycle/OXPHOS. The ability to tolerate the effects of serum or glucose deprivation indicates that integrin β3 may provide tumor cells with metabolic flexibility. Thus, we investigated whether one or more metabolic pathways were reprogrammed in response to integrin β3 expression using combined transcriptomics and targeted metabolomics in NSCLC cells with and without integrin β3 knockin. Targeted metabolomic analysis linked integrin β3 expression to a significant increase in TCA cycle metabolites and glutamine metabolism, while producing a concomitant decrease in purine metabolism, fatty acid metabolism, glycolysis/PPP, and pyrimidine metabolism pathways (Fig. 2A and B). Consistent with the metabolomics data, GSEA of RNA-seq data identified OXPHOS as the most significantly enriched energy metabolism pathway linked to integrin β3 expression (Fig. 2C), with increased expression of multiple OXPHOS complex subunits (Supplementary Fig. S2). Furthermore, supporting the metabolomics data, ectopic expression of integrin β3 or nutrient stress (low glucose) inducing β3 expression increased the levels of cellular glutamate, a major carbon source for the TCA cycle (Fig. 2D).

These results indicate that integrin β3 expression facilitates compensation for limited access to nutrients such as glucose or fatty acids...
Figure 4. Evidence linking integrin β3 and OXPHOS in human NSCLC and mouse models. A, Serial sections of the human lung cancer tissue array slides were stained for integrin β3 and ATP synthase B1. Blue, hematoxylin; brown, integrin β3. Bar = 50 μm. The graph indicates the averages of ATP synthase B1 scores (0–4 high) for integrin β3 negative (β3−) and positive (β3+) tissues. *P < 0.05, Student t test. Error bars, SE. The images show representatives of the same areas for integrin β3 and ATP synthase B1 staining. (Continued on the following page.)
Nutrient Stress-Induced Integrin αvβ3 Activates OXPHOS

Evidence linking integrin αvβ3 and OXPHOS in human NSCLC surgical biopsies and mouse models

Consistent with the in vitro findings, serial sections of patient NSCLC tissues showed a positive correlation between the expression of integrin β3 and the OXPHOS complex V protein, ATP synthase B1 (Fig. 4A), and mice bearing human NSCLC xenografts with ectopic expression of integrin β3 showed increased ATP synthase B1 expression relative to xenografts lacking β3 (Fig. 4B). Moreover, fresh lung cancer patient biopsies maintained in culture for up to nine days and challenged with low-glucose media displayed increased integrin β3 expression and MitoTracker staining (indicating mitochondrial mass and activity) compared with the tissues incubated in growth media containing normal glucose levels (Fig. 4C). These findings provide evidence linking integrin αvβ3 expression and enhanced OXPHOS metabolism in intact human or mouse tumor tissues.

We previously established that tumor cells undergoing tumor initiation can overcome isolation stress and limitations in nutrients and oxygen (17). To evaluate whether tumor initiation was associated with the activation of OXPHOS in an αvβ3-dependent manner, tumor cells with endogenous αvβ3 expression were implanted orthotopically into the mouse lungs under limiting dilution conditions to impose isolation stress. Although implantation of 0.2–5 million cells initiated detectable lung tumors in most control mice, systemic treatment with an OXPHOS inhibitor impaired tumor initiation, with a larger effect as fewer cells were injected (Fig. 4D). Furthermore, knockin of integrin β3, which induced metabolic reprogramming (Fig. 2C), was sufficient to increase tumor initiation capacity in mouse LLC cells (Fig. 4E). These findings indicate that αvβ3-positive NSCLC cells depend on OXPHOS to mitigate the isolation stress encountered during tumor initiation in vivo. Indeed, the knockout of endogenous β3 expression completely prevented tumor initiation for all cell numbers injected (Fig. 4D), further demonstrating the critical role of integrin αvβ3 in this process.

Integrin αvβ3 promotes Src-dependent sustained AMPK activation

Next, we examined the mechanisms by which integrin β3 enhances OXPHOS. Because cellular stress leads to the activation of the stress sensor, AMPK, which enables cells to undergo metabolic adaptation (18), we considered whether integrin β3 expression could lead to AMPK activation. When integrin β3-negative NSCLC cells were challenged with low glucose or low serum, AMPK was first activated (indicated by phosphorylation at T172) before integrin β3 expression was detected (Fig. 5A; Supplementary Fig. S4A). However, AMPK activation appeared in a biphasic manner, showing immediate/transient activity followed by a second sustained wave (Fig. 5A; Supplementary Fig. S4A). Interestingly, integrin β3 expression was observed 18 hours following stress, which immediately preceded the second wave of AMPK activation, which was sustained from 24 to 96 hours (Fig. 5A; Supplementary Fig. S4A). Importantly, cells expressing ectopic αvβ3 in the absence of stress displayed increased phospho-AMPK levels compared with cells lacking αvβ3 (Fig. 5B; Supplementary Fig. S4B). These findings indicate that although stress-induced integrin β3 expression does not induce immediate AMPK activity, it is sufficient to sustain AMPK activation.

PGC1α is a master regulator of mitochondrial biogenesis that can be activated by various kinases, including AMPK (19). When integrin β3-negative NSCLC cells were challenged with low glucose or serum for 96 hours, the emergence of integrin β3 expression and subsequent contained in serum by providing cells with an alternative carbon source, glutamine metabolism, to drive the TCA cycle and promote OXPHOS.

Next, we tested whether integrin β3 was necessary and/or sufficient to account for the upregulation of OXPHOS in NSCLC cells. Indeed, ectopic expressions of integrin β3 in NSCLC cells not only increased the expression of OXPHOS complexes I–V (Fig. 3A; Supplementary Fig. S3A), but are also indicators of OXPHOS function, including basal respiration, ATP production, and maximal respiration rates, measured using a Seahorse XF cell metabolic analysis (Fig. 3B; Supplementary Fig. S3B). Accordingly, the knockout or knockdown of endogenous β3 expression in αvβ3-positive NSCLC cells had the opposite effect (Fig. 3A and B). Furthermore, mitochondrial mass and membrane potential, evaluated using the mitochondrial probe MitoTracker, were increased in αvβ3-positive cells compared with those in αvβ3-negative cells (Fig. 3C). These findings indicate that upregulation of integrin αvβ3 in response to nutrient stress is necessary and sufficient to induce the expression of OXPHOS complex proteins. Given that this metabolic shift was seen in both KRAS mutant lung cancer cells (LLC and H1792) and human EGFR mutant lung cancer cells (HCC827 and H1975), the activation of OXPHOS by integrin αvβ3 appears to be independent of the primary mutation (EGFR vs. KRAS) and occurs in murine and human tumors.

Supporting these results, pharmacological inhibition of OXPHOS in αvβ3-positive cells re-sensitized them to glucose depletion in suspension (Fig. 3D), indicating that the upregulation of integrin αvβ3 induced by nutrient stress promotes stress tolerance through its capacity to activate OXPHOS. Nutrient stress not only increased the MitoTracker signal (Fig. 3E), but also upregulated the expression of OXPHOS complex proteins (Fig. 3F; Supplementary Fig. S3C). Stress-induced gain of integrin αvβ3 was required for this metabolic adaptation, as β3 knockdown prevented the gain of OXPHOS complex proteins (Fig. 3F) and OXPHOS activity (Fig. 3G; Supplementary Fig. S3D) in NSCLC cells challenged with low glucose or low serum. Together, these findings demonstrate that endogenous or stress-induced integrin αvβ3 expression switches cellular metabolic dependencies to mitochondrial respiration by increasing the expression of OXPHOS complex proteins, revealing an adaptive stress-response pathway that tumor cells can use to mitigate the effects of nutrient deprivation.
phosphorylation of AMPK led to nuclear localization (i.e., activation) of PGC1α (Fig. 5C, Supplementary Fig. S4C). Remarkably, the activation of AMPK and PGC1α was abolished by integrin β3 knockdown, demonstrating that integrin β3 is necessary for the sustained activation of the AMPK/PGC1α axis when cells sense glucose or serum deprivation (Fig. 5C, Supplementary Fig. S4C). Accordingly, AMPK and PGC1α activities were stimulated by ectopic β3 expression and suppressed by the knockout of endogenous β3 expression (Fig. 5B, Supplementary Fig. S4B).

The integrin β3 subunit contains an intracellular C-terminal domain that can recruit and activate Src. Therefore, we assessed whether the C-terminal signaling domain of integrin β3 is required for sustained activation of AMPK/PGC1α by expressing a β3/b1 chimeric integrin subunit (comprising the β3 ectodomain fused to the β1 intracellular domain) in NSCLC cells. Although expression of wild-type (WT) β3 resulted in AMPK/PGC1α activation, the β3/b1 chimera failed to do so (Fig. 5B, Supplementary Fig. S4B, and S4D), implicating the β3 cytoplasmic domain as a key component required for metabolic reprogramming. To further understand how integrin β3 signaling might influence this metabolic pathway, we created NSCLC cells expressing a β3 mutant (β3−/−79X) lacking the terminal four amino acids, a region we and others have established is specifically required for β3-mediated recruitment/activation of Src kinase in the absence of integrin ligation (Supplementary Fig. S4E; refs. 9, 20, 21). Accordingly, we show here that lung cancer cells with this β3 mutation were incapable of activating Src, failed to undergo sustained AMPK/PGC1α activation, and did not display OXPHOS complex protein expression (Fig. 5B; Supplementary Fig. S4B, and S4D; ref. 22). Furthermore, glucose or serum deprivation decreased the viability (Fig. 5D; Supplementary Fig. S4F) and sphere-forming ability (Fig. 5E) of NSCLC cells expressing the β3/b1 chimera, mutant β3 (β3−/−79X), or β3 knockout, whereas ectopic expression of full-length WT integrin β3 rescued the cells. These findings suggest that the β3/Src signaling axis is both necessary and sufficient to provide NSCLC cells with the ability to switch their metabolic function to OXPHOS, allowing them to overcome nutrient deprivation. Importantly, knockdown of liver kinase B1 (LKB1) or calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) attenuated integrin β3-mediated phosphorylation of AMPK only partially, whereas dual knockdown of LKB1 and CAMKK2 completely attenuated AMPK phosphorylation by integrin β3 (Fig. 5F), indicating that both LKB1 and CAMKK2 contribute to AMPK activation downstream from β3/Src.

Finally, we used pharmacological inhibitors as a complementary approach to determine the role of the β3/Src/AMPK signaling axis in the sustained activation of OXPHOS when cells sense nutrient depletion. Indeed, the activation of this mitochondrial stress tolerance signaling cascade by nutrient stress or endogenous integrin β3 expression was prevented by treatment with pharmacological inhibitors of nutrient stress.
AMPK or Src (Fig. 5G and H; Supplementary Fig. S4G–S4I). Supporting these data, knockdown of AMPK-α1/2 attenuated expression of OXPHOS complex proteins (Fig. 5G; Supplementary Fig. S4G). Accordingly, the ability of ectopic β3 expression to promote stress tolerance could be “negated” by an AMPK inhibitor, whereas the inability of the β3/b1 chimera, the β3–759X mutant, or β3KO/knockdown to promote stress tolerance could be “rescued” by an AMPK stimulator (Fig. 5E). In terms of biological function, treating αvβ3-positive cells with inhibitors of AMPK or PGC1α negated their ability to withstand glucose deprivation (Fig. 5I), whereas treating αvβ3-negative cells with stimulators of AMPK or PGC1α could promote nutrient stress tolerance in the absence of αvβ3 (Fig. 5J; Supplementary Fig. S4J).

Discussion

Nutrient stress is a significant obstacle that cancer cells must overcome to undergo tumor initiation and progression (23, 24). Cancer stem/tumor-initiating cells are known to express activated OXPHOS for survival by coping with reduced nutrients and an increased energy demand (25, 26). How cancer stem/tumor-initiating cells respond to nutrient stress by inducing OXPHOS remains unclear. Integrin αvβ3 is a marker/driver of cancer stem/tumor-initiating cells in various epithelial cancers (3, 9, 27). This integrin is typically absent in normal healthy tissues but is transiently upregulated during wound-repair/remodeling and cancer progression, where it has been linked to angiogenesis, tumor drug resistance, tumor cell initiation, and metastasis (3, 28, 29). Using NSCLC fresh biopsy tissues from patients as well as cultured cells, we detected stress-induced expression of integrin αvβ3 on the cell surface as an adaptive response to overcome limited access to nutrients such as glucose or serum. Specifically, nutrient stress-induced integrin αvβ3 expression allowed cells to activate the glutamine pathway when other carbon sources (glucose and serum) for TCA cycle were limited, leading to enhanced OXPHOS activity for much needed energy production.

Counterintuitively to the function of an integrin as a mediator of adhesion to the ECM, we found that cell-matrix interactions are not critical for the metabolic flexibility provided by integrin αvβ3, as we observed the switch from glycolysis to OXPHOS when cells were in suspension under serum-deprived conditions or challenged during cancer progression. Accordingly, pharmacological inhibition of AMPK decreased the levels of OXPHOS complex proteins (Fig. 5G) and diminished the stress-tolerant phenotype of integrin αvβ3-positive cells (Fig. 5E). However, blocking AMPK could have significant effects on the metabolism of normal healthy cells. As such, our finding that the β3 C-terminus is necessary and sufficient to activate the Src/AMPK axis (Fig. 5B) may represent a more selective strategy to target the role of integrin αvβ3 in cancer progression without affecting OXPHOS activity in normal cells that do not express integrin αvβ3. Indeed, treatment of cells with a Src inhibitor attenuated AMPK activation in cells with endogenous β3 expression or that induced by nutrient stress (Fig. 5H).

In summary, the cancer stem/tumor-initiating cell marker, integrin αvβ3, expressed in response to nutrient stress promotes nutrient stress tolerance and tumor initiation that depends on sustained AMPK activation (Fig. 6). The upregulation of electron transport chain proteins provides tumor cells with metabolic flexibility to shift energy production to glutamine metabolism/TCA cycle/OXPHOS when nutrients are limited (Fig. 6). Although blocking this pathway using Src inhibitors may selectively prevent cancer stem/tumor-initiating cells from becoming resistant to nutrient deprivation, such drugs may have a heightened effect when administered in combination with strategies to manipulate nutrient access and/or therapeutics that increase integrin αvβ3 levels, such as EGFR inhibitors (3) and chemotherapeutics (37).

Authors’ Disclosures

A. Nam: reports grants from National Institutes of Health (NIH) during the conduct of the study. A. Campos: reports grants from NIH during the conduct of the study. R.M. Shepard reports grants from National Science Foundation, National Institutes of Health, and California Institute for Regenerative Medicine during the conduct of the study. S.M. Weis reports grants from NIH during the conduct of the study; as well as other support from AlphaBeta Therapeutics outside the submitted work; and reports a patent for US20230140868A1 pending to AlphaBeta Therapeutics. D.A. Cheresh: reports being a co-founder of AlphaBeta Therapeutics. No disclosures were reported by the other authors.

Authors’ Contributions

A. Nam: Data curation, formal analysis, validation, investigation, visualization, methodology, writing—review and editing. S. Jain: Conceptualization, data curation, formal analysis, validation, investigation, visualization, methodology, writing—original draft. C. Wu: Data curation, formal analysis, validation, investigation, visualization. A. Campos: Data curation, formal analysis. R.M. Shepard: Resources. Z. Yu: Data curation, formal analysis, validation, investigation, visualization. J.P. Reddy: Data curation, formal analysis, visualization. T. von Schalcha: Formal analysis, validation, investigation. S.M. Weis: Conceptualization, writing—original draft, writing—review and editing. M. Onaitis: Resources. H.I. Wettersten: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, writing—review and editing. D.A. Cheresh: Conceptualization, resources, supervision, funding acquisition, writing—original draft, writing—review and editing.
Acknowledgments

We thank Drs. A. Lowy and J. Weitz (UC San Diego) for their consultation and expertise in tissue slice culture studies. Chinmayi Kashyap, Diva Sanawanl, Beatrix F. dos P. Peixoto, Rebecca Clague, and Tania Frank provided the technical assistance. This study was funded by T30FT0343 (to C. Wu), K01OD030513 and DD2204 (to H.I. Wettersten), R01CA045726 and R53CA220512 (to D.A. Cheresh), P30NS07101 (UC San Diego Microscopy Core), and P30CA23100 (UC San Diego Tissue Technology). Cody Fine, Mateo Espinoza, and Mitra Banhashan from the UCSD Human Embryonic Stem Cell Core Facility at the Sanford Institute for Regenerative Medicine provided technical assistance for flow cytometry experiments. This work was made possible by a CIRM Major Facilities grant (FA1–00667) to the Sanford Consortium for Regenerative Medicine. Metabolomic analysis was performed by the UCSD Biochemical Genetics and Metabolomics Laboratory.

Note

Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Received September 5, 2023; revised January 5, 2024; accepted February 16, 2024; published first April 8, 2024.

References